Vascular endothelium activation mechanisms study іn patients with psoriasis and essential hypertension
DOI:
https://doi.org/10.14739/2310-1210.2016.1.64070Keywords:
Vascular Endothelial Growth Factor-A, Psoriasis, Essential HypertensionAbstract
The aim. To study Vascular Endothelial Growth Factor-A expression in patients with both psoriasis and hypertension.
Methods and results. 102 patients were included. Vascular Endothelial Growth Factor-A level was detected with indirect ELISA method.
It was found that VEGF-A level was maximal in patients with psoriasis and hypertension stage II - 694.44 (567.36–829.87) pg/ml. That was statistically significantly higher (p<0,01) than in patients with psoriasis and more than 5 times (p<0,01) higher than VEGF-A levels patients with essential hypertension.
At the same time, vascular endothelial growth factor level in patients with psoriasis without essential hypertension was higher in 3.5 times (p<0,01) when compared with group of patients with essential hypertension, which did not exceed 300 pg/ml. This indicates it is most active angiogenesis in patients with a combination of psoriasis and essential hypertension.
Conclusion. The results indicated the direct relationship between the reliable indicators of VEGF-A expression and dermatosis clinical course severity in patients with both psoriasis and essential hypertension.
References
Kubanova, A. A., Nikolas, J. F., Puig, L., Prince, J., Katunina, O. R., & Znamenskaya, L. F. (2010) Immunnye mekhanizmy psoriaza. Novye strategii biologicheskoj terapii [Immune mechanisms of psoriasis. New strategies of biotherapy]. Vestnik dermatologii i venerologii, 1, 35–47. [in Russian].
Gisondi, P., Del Giglio, M., Cozzi, A., & Girolomoni, G. (2010) Psoriasis, the liver, and the gastrointestinal tract. Dermatol. Ther., 23(2), 155–159. doi: 10.1111/j.1529-8019.2010.01310.x.
Boehncke, W. H., & Boehncke, S. (2008) Research in practice: the systemic aspects of psoriasis. J. Dtsch. Dermatol. Ges., 6, 622–625. doi: 10.1111/j.1610-0387.2008.06785.x.
Sukharev, A. V., Nazarov, R. N., Yurchik, M. I., & Patrushev, A. V. (2009) Vul′garnyj psoriaz: osobennosti patogeneza i terapii [Psoriasis vulgaris: the specific features of its pathogenesis and therapy]. Rossijskij zhurnal kozhnykh i venericheskikh boleznej, 2, 23–26. [in Russian].
Mak, R. K., Hundhausen, S., & Nestle, F. O. (2009) Progress in understanding the immunopathogenesis of psoriasis. ActasDermo-Sifiliograficas, 100(2), 2–13.
Kurdina, M. I., & Makarenko, L. A. (2009) Kompleksnaya ocenka bezopasnosti lecheniya bol′nykh psoriazom khimernymi monoklonal′nymi antitelami k FNO-a [Integrated Safety Assessment of treatment of psoriasis patients with chimeric monoclonal antibody to TNF-alpha]. Abstracts of Papers of the 3rd All-Russian Congress of dermatologists, (S. 45). Moscow. [in Russian].
Gisondi, P., Giglio, M. D., Cozzi, A., & Girolomoni, G. (2010) Psoriasis, the liver, and the gastrointestinal tract. Dermatolodic Therapy., 23(2), 155–159. doi: 10.1111/j.1529-8019.2010.01310.x.
Pathirana, D., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P., & Nast, A. (2009) European S3-Guidelines on the systemic treatment of psoriasis vulgaris. JEADV, 23(2), 70. doi: 10.1111/j.1468-3083.2009.03389.x.
Peternel, S., & Kastelan, M. (2009) Immunopathogenesis of psoriasis: focus on natural killer T cells. J. Eur. Acad. Dermatol. Venereol., 23(10), 1123–1127. doi: 10.1111/j.1468-3083.2009.03292.x.
Yan, K. X., Fang, X., Han, L., Zhang, Z. H., Kang, K. F., Zheng, Z. Z., & Huang, Q. (2010) Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris. Br. J. Dermatol, 163, 48–56. doi: 10.1111/j.1365-2133.2010.09742.x.
Dzherieva, I. S., & Volkova, N. I. (2010) Arterial′naya gipertenziya i metabolicheskie narusheniya [Arterial hypertension and metabolic disorders]. Klinicheskaya medicina, 88(2), 4–8. [in Russian].
Bunova, S. S. (2009) Vklad nejrogumoral′noj disfunkcii i povyshennoj massy tela v techenie gipertonicheskoj bolezni [Contribution of neurohumoral dysfunction and overweight to the course of essential hypertension]. Terapevticheskij arkhiv, 81(5), 71–74. [in Russian].
Drobotya, N. V., Doltmurzieva, N. S., Gusejnova, E′. Sh., & Drobotya, A. A. (2010) E′ffekty gipotenzivnoj terapii na sostoyanie sosudistoj stenki u bol′nykh arterial′noj gipertoniej [The effects of antihypertensive therapy on the vascular wall in hypertensive patients]. Klinicheskaya farmakologiya i terapiya, 19(4), 30–32. [in Russian].
Coleman, S. K., Möykkynen, T., Hinkkuri, S., Vaahtera, L., Korpi, E. R., Pentikäinen, O. T., & Keinänen, K. (2010) Ligand-binding domain determines endoplasmic reticulum exit of AMP A receptors. J. Biol. Chem., 285(46), 36032–36039. doi: 10.1074/jbc.M110.156943.
Borselli, C., Storrie, H., Benesch-Lee, F., Shvartsmana, D., Cezara, C., Lichtmane, J. W., et al. (2010) Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. ProcNatlAcadSci USA, 107(8), 3287–92. doi: 10.1073/pnas.0903875106.
Beohar, N., Rapp, J., Pandya, S., & Losordo, D. W. (2010) Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am CollCardiol, 56(16), 1287–97. doi: 10.1016/j.jacc.2010.05.039.
Anderson, K. S., Petersson, S., Wong, J., Shubbar, E, Lokko, N. N., Carlström, M., & Enerbäck, C. (2010) Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br. J. Dermatol., 163(5), 1085–89. doi: 10.1111/j.1365-2133.2010.09990.x.
Matushevskaya, Yu. I. (2009) Ocenka e′ffektivnosti terapii bol′nykh tyazhelymi formami psoriaza s primeneniem genno-inzhenernogo biologicheskogo preparata infliksimab na osnovanii klinicheskikh i immunologicheskikh pokazatelej (Avtoref. dis …kand. med. nauk). [Estimation of efficiency treatment of patients with severe psoriasis with the use of genetically engineered biological drug infliximab based on clinical and immunological parameters]. (Extended abstract of candidate’s thesis). Moscow. [in Russian].
Patel, R. V., Clark, L. N., Lebwohl, M., & Weinberg, J. M. (2009) Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol, 60, 100–117. doi: 10.1016/j.jaad.2008.12.031.
Li, Y., Liao, W., Chang, M., Schrodi, S. J., Bui, N., Catanese, J J., et al. (2009) Further genetic evidence for three psoriasis risk genes: ADAM33, CDKAL1, and PTPN22. J. Invest. Dermatol, 129, 629–34. doi: 10.1038/jid.2008.297.
Ketlinskij, S. A., & Simbircev, A. S. (2008) Citokiny [Cytokines]. Saint Petersburg: Foliant. [in Russian].
Myung, S. J., Yoon, J. H., Kim B. H. Lee, J. H., Jung, E. U., & Lee, H. S. (2009) Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells. J Pharmacol ExpTher., 330(1), 276–282. doi: 10.1124/jpet.109.151860.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
